- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01887431
Telecare in Type 1 Diabetes (T1D) Patients Treated by Insulin Pump
Telecare in Adults With Type 1 Diabetes Mellitus Treated by Insulin Pump - A Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objectives
- To evaluate the effect of telecare on glycemic control for patients with type 1 diabetes (T1DM).
- To assess the cost of telecare to Maccabi, the patient and the economy.
- To assess patients' quality of life and satisfaction with telecare intervention.
- To assess the effect of telecare intervention on insulin adjustment to consumed carbohydrates.
- Working hypothesis Telecare can be used for efficient management of T1DM in adults using insulin pump, in lieu of frequent clinic visits.
Methodology A randomized controlled prospective trial for one year. Intervention group: Each patient will transmit glucometer and pump data electronically via a web site (Medtronic Carelink internet site www.carelink.minimed.com) to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control. In addition to data transmission Patient of the intervention group will be arriving during the intervention year for 3 clinic visit at the following time point : 0, 6 and 12 month.
Control group: 3-month routine clinic visits
- Significance of the proposed research (its uniqueness and innovation) Telecare potentially offers a method for efficient continuous care management of patients with T1DM using insulin pump in lieu of clinic visits. It enables real time responses of clinical personnel and increases patient involvement. This trial will be the first telecare intervention lasting for one year to determine if treatment is as efficient as face to face visits, thus enabling cost reduction and time saving without affecting the quality of care. .
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Ra'anana, Israel
- Maccabi Healthcare Services
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with T1D lasted >1 year, age 22 and up, using insulin pump
- Patients possessing a mobile phone and internet access
Exclusion Criteria:
- Patients with Severe target organ damage
- Patients with Mental retardation
- Patients with Eating disorders
- Pregnant patients or patients planning pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Telecare
Each patient will transmit glucometer and pump data electronically via a web site to diabetes team and will receive feedback by telephone.
Frequency of data transfer will be directly related to patients' metabolic control.
|
Each patient will transmit glucometer and pump data electronically via a web site (Medtronic Carelink internet site www.carelink.minimed.com)
to diabetes team and will receive feedback by telephone.
Frequency of data transfer will be directly related to patients' metabolic control.
In addition to data transmission Patient of the intervention group will be arriving during the intervention year for 3 clinic visit at the following time point : 0, 6 and 12 month.
|
Active Comparator: Conventional therapy
3-month routine clinic visits
|
3-month routine clinic visits
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Glycosylated Hemoglobin (Hba1c)
Time Frame: From date of randomization every 3 months, up to one year
|
From date of randomization every 3 months, up to one year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time spent on data analysis and telephone calls by team
Time Frame: 1 year
|
1 year
|
Number of severe hypoglycemic and diabetic ketoacidosis (DKA) events and hospitalizations
Time Frame: 1 year
|
1 year
|
Patients' quality of life
Time Frame: 1 year
|
1 year
|
Patients' satisfaction
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 71156
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on Telecare
-
The Hong Kong Polytechnic UniversityThe Queen Elizabeth HospitalCompleted
-
The Hong Kong Polytechnic UniversityCompleted
-
Elizabeth K RhodusRecruiting
-
Istituti Clinici Scientifici Maugeri SpAIstituto Auxologico Italiano; Azienda Ospedaliera Bolognini di Seriate Bergamo and other collaboratorsCompleted
-
University Hospital of North NorwayUnknownCongestive Heart FailureNorway
-
The Hong Kong Polytechnic UniversityTuen Mun HospitalRecruitingDiabetes MellitusHong Kong
-
The Hong Kong Polytechnic UniversityThe Queen Elizabeth HospitalRecruiting
-
Physio-AssistIcadomCompletedBronchiectasis AdultFrance
-
University of UtahNational Cancer Institute (NCI)CompletedColorectal CancerUnited States
-
Amsterdam UMC, location VUmcUnknown